regadenoson has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, L; Gou, S; Liu, Q; Liu, Z; Zhang, B | 1 |
| Bynoe, MS; Carman, AJ; Kim, DG; Krenz, A; Mills, JH | 1 |
2 other study(ies) available for regadenoson and Alzheimer Disease
| Article | Year |
|---|---|
Blood-Brain Barrier Permeable and NO-Releasing Multifunctional Nanoparticles for Alzheimer's Disease Treatment: Targeting NO/cGMP/CREB Signaling Pathways.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Line, Tumor; Donepezil; Drug Carriers; Drug Liberation; Humans; Indazoles; Male; Memory; Mice, Inbred BALB C; Mice, Nude; Multifunctional Nanoparticles; Neuronal Plasticity; Neurons; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Donors; Nootropic Agents; Oxadiazoles; Purines; Pyrazoles; Rats, Sprague-Dawley; Signal Transduction | 2021 |
Adenosine receptor signaling modulates permeability of the blood-brain barrier.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antibodies; Blood-Brain Barrier; Cells, Cultured; Dextrans; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Permeability; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Receptor, Adenosine A1; Receptors, Adenosine A2; Tight Junctions | 2011 |